Viking Therapeutics (VKTX) Operating Leases (2019 - 2025)

Viking Therapeutics has disclosed Operating Leases across 6 years of filings, most recently posting $318000.0 for Q3 2025.

• Operating Leases for Q3 2025 came in at $318000.0, down 57.88% year-over-year; the trailing twelve-month figure through Sep 2025 was $318000.0 (down 57.88% YoY), and the FY2024 annual result was $630000.0, down 32.69% from the prior year.
• Operating Leases came in at $318000.0 for Q3 2025 at Viking Therapeutics, down from $410000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $1.5 million in Q1 2022 to a low of $318000.0 in Q3 2025.
• The 4-year median for Operating Leases is $936000.0 (2023), against an average of $931266.7.
• Across the five-year window, Operating Leases slipped 20.74% in 2023 and tumbled 57.88% in 2025, its largest moves.
• Viking Therapeutics' Operating Leases stood at $1.3 million in 2022, then declined by 25.71% to $936000.0 in 2023, then plunged by 32.69% to $630000.0 in 2024, then sank by 49.52% to $318000.0 in 2025.
• The last three Operating Leases figures came in at $318000.0 (Q3 2025), $410000.0 (Q2 2025), and $502000.0 (Q1 2025), per Business Quant data.